Adgyl Life Sciences

Adgyl Life Sciences is a premier contract research organization (CRO) offering comprehensive in vivo pharmacology and GLP safety assessment services to support drug discovery, preclinical, and early clinical development programs. With a strong regulatory foundation and world-class expertise, Adgyl specializes in enabling global regulatory submissions across pharmaceuticals, biologics, medical devices, agrochemicals, and more.

Our Expertise

We provide a full spectrum of services covering:

• Drug Discovery & Development – Supporting discovery, preclinical, and non-clinical NDA submissions.
• Safety Assessment – Conducting regulatory and standalone studies to facilitate human trials.
• Pharmacokinetics & Bioanalysis – Ensuring comprehensive drug metabolism and pharmacokinetics (DMPK) evaluation.

Certifications & Accreditations

Adgyl boasts a team of highly qualified professionals, including:
✅ 8 U.S. Board-Certified Toxicologists (DABT)
✅ 6 European Registered Toxicologists (ERT)
✅ 4 Diplomates of the Indian Board of Toxicopathology (DIBTP)

Proven Impact

With 329+ non-rodent studies, 25,000+ regulatory tests, and 500+ standalone studies, our contributions have been instrumental in supporting numerous IND, NDA, and global regulatory filings.

Industry Focus

We cater to various sectors, including:
✔ Pharmaceutical & Biotech
✔ Veterinary Pharmaceuticals
✔ Nutraceuticals & Novel Foods
✔ Agrochemicals
✔ Biologics & Vaccines
✔ Medical Devices
✔ Cosmetics & REACH Studies

Why Choose Adgyl?

🔹 Regulatory Excellence – Expertise in global compliance for FDA, EMA, and other regulatory agencies.
🔹 Innovative Solutions – Cutting-edge research in DMPK, toxicology, bioanalysis, and carcinogenicity studies.
🔹 Proven Track Record – Recognized for contributions to successful IND applications, including TT-4, a first-in-class Adenosine A2B receptor (A2BR) Antagonist.

At Adgyl Life Sciences, we are committed to accelerating drug development through scientific excellence and regulatory expertise.